Annual CFF
$15.79 M
+$15.79 M+100.00%
31 December 2023
Summary:
Aileron Therapeutics annual cash flow from financing activities is currently $15.79 million, with the most recent change of +$15.79 million (+100.00%) on 31 December 2023. During the last 3 years, it has fallen by -$6000.00 (-0.04%). ALRN annual CFF is now -71.62% below its all-time high of $55.66 million, reached on 31 December 2021.ALRN Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$446.00 K
-$18.71 M-102.44%
30 September 2024
Summary:
Aileron Therapeutics quarterly cash flow from financing activities is currently -$446.00 thousand, with the most recent change of -$18.71 million (-102.44%) on 30 September 2024. Over the past year, it has dropped by -$446.00 thousand (-100.00%). ALRN quarterly CFF is now -100.80% below its all-time high of $55.60 million, reached on 31 March 2021.ALRN Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$33.61 M
-$446.00 K-1.31%
30 September 2024
Summary:
Aileron Therapeutics TTM cash flow from financing activities is currently $33.61 million, with the most recent change of -$446.00 thousand (-1.31%) on 30 September 2024. Over the past year, it has increased by +$33.61 million (+100.00%). ALRN TTM CFF is now -52.93% below its all-time high of $71.40 million, reached on 31 March 2021.ALRN TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALRN Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +100.0% | -100.0% | +100.0% |
| 3 y3 years | -0.0% | -1815.4% | -43.9% |
| 5 y5 years | +528.0% | -774.5% | +33.1% |
ALRN Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -71.6% | -102.4% | at low | -43.9% | ||
| 5 y | 5 years | -71.6% | -100.8% | at low | -52.9% | ||
| alltime | all time | -71.6% | +1262.2% | -100.8% | at low | -52.9% |
Aileron Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$446.00 K(-102.4%) | $33.61 M(-1.3%) |
| June 2024 | - | $18.26 M(+15.6%) | $34.06 M(+115.6%) |
| Dec 2023 | $15.79 M(>+9900.0%) | $15.79 M(>+9900.0%) | $15.79 M(>+9900.0%) |
| Sept 2023 | - | $0.00(0.0%) | $0.00(0.0%) |
| June 2023 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2022 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Sept 2022 | - | $0.00(0.0%) | $1000.00(-96.3%) |
| June 2022 | - | $0.00(0.0%) | $27.00 K(-49.1%) |
| Mar 2022 | - | $0.00(-100.0%) | $53.00 K(-99.9%) |
| Dec 2021 | $55.66 M(+252.3%) | $1000.00(-96.2%) | $55.66 M(-7.1%) |
| Sept 2021 | - | $26.00 K(0.0%) | $59.90 M(-0.5%) |
| June 2021 | - | $26.00 K(-100.0%) | $60.17 M(-15.7%) |
| Mar 2021 | - | $55.60 M(+1210.8%) | $71.40 M(+351.9%) |
| Dec 2020 | $15.80 M(-34.1%) | $4.24 M(+1323.5%) | $15.80 M(+36.9%) |
| Sept 2020 | - | $298.00 K(-97.4%) | $11.54 M(+3.1%) |
| June 2020 | - | $11.26 M(>+9900.0%) | $11.19 M(-53.0%) |
| Mar 2020 | - | $0.00(-100.0%) | $23.80 M(-0.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | $23.96 M(+852.8%) | -$15.00 K(-70.6%) | $23.96 M(-5.1%) |
| Sept 2019 | - | -$51.00 K(-100.2%) | $25.26 M(-4.8%) |
| June 2019 | - | $23.86 M(>+9900.0%) | $26.52 M(+895.4%) |
| Mar 2019 | - | $165.00 K(-87.1%) | $2.66 M(+5.9%) |
| Dec 2018 | $2.52 M(-95.0%) | $1.28 M(+5.5%) | $2.52 M(+153.0%) |
| Sept 2018 | - | $1.21 M(>+9900.0%) | $994.00 K(-98.0%) |
| June 2018 | - | $12.00 K(-25.0%) | $50.49 M(+0.9%) |
| Mar 2018 | - | $16.00 K(-106.6%) | $50.04 M(-1.1%) |
| Dec 2017 | $50.59 M(+58.2%) | -$244.00 K(-100.5%) | $50.59 M(-27.5%) |
| Sept 2017 | - | $50.70 M(<-9900.0%) | $69.80 M(+265.4%) |
| June 2017 | - | -$436.00 K(-176.6%) | $19.10 M(-1.9%) |
| Mar 2017 | - | $569.00 K(-97.0%) | $19.47 M(-39.1%) |
| Dec 2016 | $31.99 M(-2453.6%) | $18.96 M(>+9900.0%) | $31.99 M(+145.6%) |
| Sept 2016 | - | $8000.00(-112.3%) | $13.03 M(+0.1%) |
| June 2016 | - | -$65.00 K(-100.5%) | $13.02 M(-0.5%) |
| Mar 2016 | - | $13.08 M | $13.08 M |
| Dec 2015 | -$1.36 M | - | - |
FAQ
- What is Aileron Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Aileron Therapeutics?
- What is Aileron Therapeutics annual CFF year-on-year change?
- What is Aileron Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Aileron Therapeutics?
- What is Aileron Therapeutics quarterly CFF year-on-year change?
- What is Aileron Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Aileron Therapeutics?
- What is Aileron Therapeutics TTM CFF year-on-year change?
What is Aileron Therapeutics annual cash flow from financing activities?
The current annual CFF of ALRN is $15.79 M
What is the all time high annual CFF for Aileron Therapeutics?
Aileron Therapeutics all-time high annual cash flow from financing activities is $55.66 M
What is Aileron Therapeutics annual CFF year-on-year change?
Over the past year, ALRN annual cash flow from financing activities has changed by +$15.79 M (+100.00%)
What is Aileron Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of ALRN is -$446.00 K
What is the all time high quarterly CFF for Aileron Therapeutics?
Aileron Therapeutics all-time high quarterly cash flow from financing activities is $55.60 M
What is Aileron Therapeutics quarterly CFF year-on-year change?
Over the past year, ALRN quarterly cash flow from financing activities has changed by -$446.00 K (-100.00%)
What is Aileron Therapeutics TTM cash flow from financing activities?
The current TTM CFF of ALRN is $33.61 M
What is the all time high TTM CFF for Aileron Therapeutics?
Aileron Therapeutics all-time high TTM cash flow from financing activities is $71.40 M
What is Aileron Therapeutics TTM CFF year-on-year change?
Over the past year, ALRN TTM cash flow from financing activities has changed by +$33.61 M (+100.00%)